Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340518 | 1.00 | GPBAR1 (0.34) | GPBAR1P2RX7SCN9AEIF4EBP1CYP1A2 | |
| SCHEMBL30509037 | 0.93 | GPBAR1 (0.33) | GPBAR1P2RX7SCN9AEIF4EBP1CYP1A2 | |
| SCHEMBL3337468 | 0.93 | GPBAR1 (0.33) | GPBAR1P2RX7SCN9AEIF4EBP1CYP1A2 | |
| SCHEMBL3337450 | 0.92 | GPBAR1 (0.36) | GPBAR1P2RX7SCN9AEIF4EBP1CYP3A4 | |
| SCHEMBL3338981 | 0.91 | GPBAR1 (0.33) | GPBAR1P2RX7SCN9AEIF4EBP1 | |
| SCHEMBL4752977 | 0.90 | S1PR4 (0.33) | GPBAR1SCN9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3336740 | 0.90 | GPBAR1 (0.32) | GPBAR1SCN9AALDH1A1SLC22A12 | |
| SCHEMBL3333557 | 0.89 | GPBAR1 (0.41) | GPBAR1 | |
| SCHEMBL3342070 | 0.89 | GPBAR1 (0.36) | GPBAR1SCN9AALDH1A1S1PR4 | |
| SCHEMBL3336919 | 0.88 | S1PR4 (0.33) | GPBAR1SCN9AEIF4EBP1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | GPBAR1 76/4885P2RX7 793/4885SCN9A 2480/4885 |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GPBAR1 76/4885P2RX7 793/4885SCN9A 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.